Company Profile
Sinocelltech Group Limited, a biopharmaceutical company provides the research, development, and production of recombinant proteins, antibody drugs, viral infections, and vaccines in China.
The company offers Anjiayin, a third-generation recombinant coagulation factor VIII product for the treatment of hemophilia A. Its portfolio also includes Anpingxi, an anti-CD20 monoclonal antibody for the treatment of CD20-positive diffuse large B-cell non-Hodgkin's lymphoma, Anjiarun, an adalimumab biosimilar for the treatment of various autoimmune diseases, Anbezu, a bevacizumab biosimilar for the treatment of various solid tumors, SCTV01, a series of recombinant protein vaccines for multiple variants of the new coronavirus, Fenolimab, a recombinant humanized anti-PD-1 monoclonal antibody for the treatment of solid tumors, and SCT1000, a recombinant 14-valent human papillomavirus (HPV) virus-like particle vaccine for the prevention of various cancers.
It also develops other clinical-stage products, including SCT650C for the treatment of plaque psoriasis, axial spondylarthritis, and autoimmune diseases. Its portfolio also includes SCTC21C for the treatment of CD38-positive blood cancers, SCTB35 for the treatment of diseases, such as CD20-positive B-cell non-Hodgkin's lymphoma, SCTB14 for immunotherapy of multiple solid tumors, SCTB41 for multiple solid tumor immunotherapy, SCTV02 to prevent respiratory diseases, SCTV04C to prevent herpes zoster, SCT520FF, an anti-angiogenic biopharmaceutical product, and SCTT11 for the treatment of thyroid eye disease. Founded in 2007, the company is based in Beijing, China. Sinocelltech Group Limited operates as a subsidiary of Lhasa Aili Investment Consulting Co., Ltd.